The maintenance of a Buy rating indicates continued analyst confidence in Leap Therapeutics' fundamentals, potentially offsetting the negative sentiment from a lowered price target. The reduction in price target might reflect adjustments in valuation models or market conditions, but the Buy rating suggests an overall positive outlook. Investors may view the price target adjustment as a recalibration rather than a loss of faith, leading to a neutral short-term impact.